CABA

Cabaletta Bio, Inc. is a clinical-stage biotechnology company based in Philadelphia, Pennsylvania, specializing in the development of advanced T-cell therapies aimed at targeting B-cell-mediated autoimmune diseases. With a robust pipeline driven by proprietary research and a commitment to improving patient outcomes, the company is positioned to transform treatment paradigms in this sector. Leveraging its expertise in immunotherapy and focusing on patient-centric initiatives, Cabaletta Bio presents an attractive investment opportunity for institutional investors looking to capitalize on innovative solutions in the biopharmaceutical industry.